BIOTECHNOLOGY IN EUROPE - PowerPoint PPT Presentation

Loading...

PPT – BIOTECHNOLOGY IN EUROPE PowerPoint presentation | free to view - id: ff13-NTZiZ



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

BIOTECHNOLOGY IN EUROPE

Description:

European association of biotechnology industries (b. 1996) About 35 corporate members plus 24 national. member associations representing over 1200 ... – PowerPoint PPT presentation

Number of Views:67
Avg rating:3.0/5.0
Slides: 19
Provided by: ALTI4
Category:

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: BIOTECHNOLOGY IN EUROPE


1
BIOTECHNOLOGY IN EUROPE EuropaBio http
//www.europabio.org
Warsaw 08/09.07.04
2
EuropaBio ? European association of biotechnolo
gy industries (b. 1996) ? About 35 corporat
e members plus 24 national member association
s representing over 1200 entrepreneurial comp
anies (incl. Hungary, Estonia)
? Also open to service companies, research
institutions, bioregions etc. as associate
members ? Active in all sectors healthcare, agro
, food, industrial biotech, environment, youn
g business development
3
Biotechnology areas
  • EuropaBio members are involved in three main
    biotech areas
  • Industrial biotech/White
  • Healthcare biotech/Red
  • Plant biotech /Green

4
Industrial or White biotechnology
  • The replacement of fossil fuel by renewable raw
    materials (biomass).
  • The replacement of a conventional,
    non-biological process by one based on
    biological systems, such as whole cells or
    enzymes, used as reagents or catalysts
    (bioprocesses).
  • The development of new bioproducts and biofuel

5
Global Carbon Cycle (Narayan, 2002)

6
Economy EUR 11 - 22 billion annual added value
by 2010
  • McKinsey estimate of annual added value by the
    global chemical industry
  • EUR billions
  • Impact of white biotechnology
  • Cost reduction
  • 11 - 22
  • Raw materials
  • Process costs
  • Investments
  • 6 - 12
  • Additional revenues
  • 5 - 10
  • New products
  • Value-added processes

7
Industrial biotechnology impact on
sustainibility
8
Other studies the Öko-Institute
The report can be consulted at
www.europabio.org
9
Healthcare or Red Biotechnology
  • A fast growing field within modern medicine
  • In human health, the benefits of biotechnology
    are evident and the prospects are bright.
    Solutions for diseases which so far have been
    incurable will in great part be due to the
    revolution that biotechnology brings.

10
What is Healthcare Biotech?
  • Tools to support the human body to utilize its
    own capacities to fight infectious or cancerous
    diseases.
  • Opening new possibilities to prevent, treat and
    cure with novel methods of treatment and
    diagnosis, such as
  • Production of new Medicines and Vaccines
  • Development of peptides and monoclonal
    antibodies
  • Genetic diagnostics
  • Gene therapy
  • Stem cell research
  • Cloning
  • Xenotransplantation
  • …

11
Why Healthcare Biotech is important ?
  • To meet unmet medical needs with innovative
    treatments.
  • -treatments available for just 10 000 of the 30
    000 known
  • diseases.
  • -increase in the number of disease targets for
    conventional
  • drug therapy from 500 today to nearly 10 000 in
    the future.
  • -20-30 million Europeans affected by 5000 rare
    diseases
  • powerful tools to develop diagnostics and
    treatments for orphan
  • diseases.
  • To make medical treatment more comprehensive and
    highly individualized with tailor-made
    medicines.
  • To move from treatment towards disease prevention
    and cure with improvements in diagnosis.

12
What is Plant or Green biotech?
  • Plant Biotechnology is a rapidly expanding area
    within the field of modern biotechnology
  • Plant Biotechnology can be described as the
    application of science to study plants and
    develop tools that enable the sustainable use of
    plants for food production, feed production and
    the production of other non-food/feed renewable
    materials
  • As is the case in modern biotechnology generally,
    the recent, rapid advances in mapping genomes
    together with our growing understanding of gene
    function, protein structure, etc., provide new
    tools for the breeding of crop plants, fruits and
    vegetables and trees that provide us with
    necessary resources in an environmentally
    responsible and sustainable way
  • One of the techniques of modern plant
    biotechnology is genetic manipulation (GM) also
    known as genetic engineering. This is the
    manipulation of genes at the level of the
    chromosome base pairs. It can include the
    introduction of foreign genes into the plant of
    interest thus achieving desired characteristics
    not easily achieved using other means

13
Why is Green biotechnology important?
  • Modern Plant Biotechnology is a tool that can be
    effectively used to
  • Improve sustainable agronomy (the growing of the
    plants)
  • by resisting insect pests, fungal, bacterial and
    viral diseases, competing better with weeds etc.
    while using fewer inputs and sprays
  • by changing cropping practices so reducing soil
    erosion, reducing energy (fossil fuel) use and
    greenhouse gas emissions
  • by enabling plants to grow in stressful
    conditions while using available nutrients more
    efficiently
  • etc.
  • Assist with improving and diversifying the
    products derived from plants
  • by improving the starch, protein and oil products
    derived from our traditional plants
  • by using plants to provide feeder stocks for
    industrial process (e.g., providing plastics,
    renewable energy, etc.)
  • by enabling plants to produce high value products
    (e.g., functional foods, nutraceuticals,
    pharmaceuticals, etc.)
  • etc.

14
Europabio Mission Statement EuropaBios mission
is to promote an innovative and dynamic
biotechnology based industry in Europe.
We advocate free and open markets and the remova
l of barriers to competitiveness with other areas
of the world. We champion the responsible use o
f biotechnology to ensure that its potential is
fully used to the benefit of humans and their
environment. We are committed to an open, infor
med dialogue with all stakeholders about the
ethical, social and economic aspects of
biotechnology and its applications.

15
Biotechnology Market Potential
An ever-growing cake, but what size is Europes
slice ? ? worldwide, by 2010, over 2000 billi
on worth of products and services will be biot
ech, biotech- derived or biotech-processed
? worldwide, by 2010, biotech will create 3
million new jobs (direct indirect) ? alrea
dy now, over half of medicines in clinical
trials (the drugs of tomorrow) are of biotech
origin European Commission estimate Jan.
2002

16
Europes Ambitions The Lisbon Targets for 2010
  • ? In April 2000, the European Council (all EU
    government leaders) declared that Europe was to
    become the most competitive and dynamic
    knowledge-based economy in the world by 2010.
  • ? This implied net creation of 15 mio. new jobs
    and increasing labour participation from about
    60 to 70 (the stable US rate)
  • New technologies and biosciences in particular,
    were to play key role in reaching these targets.
  • In 2002 (Barcelona), the European Council added a
    specific RD target increase spending from 1.9
    of GDP to 3 of GDP


17
What European biotech needs ? stimulating measur
es, with fast effect, for young innovative
enterprises (e.g. Young Innovative Company
tax status in France) ? harmonised EU-wide capita
l market rules, leading to a single European
venture capital and stock market
? public money to encourage matching private
funding for early rounds of financing
? high rewards for high risks, through incentives
and benefits ? successful projects, companies a
nd entrepreneurs to act and be mediatised as
champions and role models

18
What European biotech needs ? science made mor
e attractive for students business made more
attractive for scientists ? scientists trained to
explain (not defend) their work to the
public ? simple, stable, enabling regulations
? a strong political leadership, at EU but even
more at national level ? a solid alliance amon
g the most determined Member States, to lead
the effort and make others follow
About PowerShow.com